Join to access to all OVN content. Join for Free
Career Satisfaction and Growth: What factors MUST be considered
MSL career satisfaction company culture evaluation aligning core values effective company research MSL roles evolution

Career Satisfaction and Growth: What factors MUST be considered


Share This Article


Summary

In this episode, Tom Caravela is joined by Beth Kupferer to discuss career satisfaction and adaptation in the MSL field. Beth shares insights from her career journey, emphasizing the importance of evaluating leadership, company culture, and aligning with core values. The conversation delves into effective company research and key interview questions. Beth and Tom explore the evolution of MSL roles and team structures post-COVID, highlighting the significance of networking and adapting to KOL preferences. They also discuss the value of live meetings and conferences in the current landscape. The episode concludes with listener appreciation and a request for feedback.

My guest today is Beth Kupferer, National Director, Women’s Health at AbbVie, and we discuss the factors most important for career satisfaction and growth

Beth discusses…

πŸ‘‰ What people need to know when determining next steps for their careers
πŸ‘‰ How people should research companies prior to making the decision to join
πŸ‘‰ What people should be looking for in a company
πŸ‘‰ What MSLs can do to help grow their career
πŸ‘‰ How critical it is for company values to align with personal values
πŸ‘‰ Questions to prepare and ask during an interview

Click for Source
MSL career satisfaction, company culture evaluation, aligning core values, effective company research, MSL roles evolution

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Explore OVN